Psilocybe

Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

Retrieved on: 
Tuesday, April 2, 2024

Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.

Key Points: 
  • Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.
  • The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications.
  • The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption.
  • “Obtaining successful results on the validation batches of psilocybin extract speaks to Optimi’s dedication to developing a repeatable, quality focused manufacturing process.

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Retrieved on: 
Tuesday, November 7, 2023

The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.

Key Points: 
  • The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.
  • PurMinds™ is currently able to supply its psilocybin mushrooms in dried whole mushroom form, or milled and encapsulated, with potency analyses reaching average total tryptamine levels of up to 1.03%.
  • To support patient safety and practitioner confidence, each batch is also tested for impurities.
  • "The specialized expertise that our scientists and cultivation team possess, coupled with the Company's strong focus on safety, efficacy and profitability, has ideally positioned PurMinds to be at the forefront of legal natural psilocybin mushroom supply."

The Mind-bending Mushroom: Expanding Consciousness and Cultural Acceptance of Psychedelic Alkaloids as Medicinal Tools, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, November 2, 2023

TORONTO, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Mushrooms have been used in medicinal and spiritual practices by Indigenous cultures around the world for several millennia. Because of renewed interest in entheogenic plant molecules as therapeutics, there is a large body of research building around psychedelic alkaloids found in the fungi kingdom. The three most studied genera include Psilocybe, Amanita and Claviceps, each with its own infamous history.

Key Points: 
  • In this free webinar, learn about the history, chemistry and pharmacology behind some of the most notorious alkaloids in human history.
  • The featured speaker will discuss the pharmacology and chemistry of tryptamines, beta-carbolines, isoxazoles and ergolines classes of alkaloids and their use in psychedelic medicine.
  • TORONTO, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Mushrooms have been used in medicinal and spiritual practices by Indigenous cultures around the world for several millennia.
  • Join this webinar and learn about the history, chemistry and pharmacology behind some of the most notorious alkaloids in human history.

QualitySpores.store Announces Strategic Acquisitions of BetterMushroomSpores.com and FreeBirdMushroomSpores.com

Retrieved on: 
Thursday, September 7, 2023

Domain Acquisition Marks a Major Milestone

Key Points: 
  • Details of the financial transaction revealed that the combined cost of acquiring the two domains stood at approximately $350,000.
  • This strategic investment signifies QualitySpores.store's dedication to long-term growth and confidence in the mushroom spore industry's potential.
  • The integration process will begin immediately, ensuring seamless experiences for all existing and new customers.
  • As the mushroom spore industry continues to gain popularity and mainstream acceptance, QualitySpores.store aims to stay at the forefront by exploring further strategic acquisitions and partnerships.

Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market

Retrieved on: 
Wednesday, May 17, 2023

In preparation for the international export, the Company harvested 300 kg of Psilocybe cubensis mushrooms at its Canadian GMP manufacturing facility in Princeton, British Columbia, Canada.

Key Points: 
  • In preparation for the international export, the Company harvested 300 kg of Psilocybe cubensis mushrooms at its Canadian GMP manufacturing facility in Princeton, British Columbia, Canada.
  • Medical-grade GMP psilocybin is set to be extracted from the mushrooms, processed, and shipped to Australia, where it will be sold to other licensed entities in the Australian medical market through Mind Medicine Australia and the Company’s representatives.
  • “The evidence-based decision by the TGA to reschedule psilocybin and MDMA is a positive step for the future of mental health and a monumental undertaking in logistics,” said Optimi Health CEO Bill Ciprick.
  • “To be entrusted as the exclusive supplier to Mind Medicine Australia, the largest Australian trainer of psychedelic-assisted therapy practitioners, is both an honour and a tremendous responsibility.

Lickable toads and magic mushrooms: wildlife traded on the dark web is the kind that gets you high

Retrieved on: 
Thursday, May 4, 2023

But alongside legal trade in wildlife, there’s a dark twin – illegal trading of wildlife.

Key Points: 
  • But alongside legal trade in wildlife, there’s a dark twin – illegal trading of wildlife.
  • In our new research, we probed the dark web – the secretive section of the internet deliberately set up out of view of search engines.
  • These were almost entirely plants and fungi with psychoactive effects, indicating they are part of the well-known dark web drug trade.
  • Why aren’t traders in illegal wildlife using the dark web?

What was being sold on the dark web?

    • We found over 3,000 advertisements selling wildlife species on dark web marketplaces between 2014 and 2020.
    • Plants made up most of the species being sold, with many coming from Central and Southern America.
    • We also found 19 species of Psilocybe fungi being sold.

The illegal wildlife trade is hard to stop

    • Globally, the wildlife trade is regulated by the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES).
    • The number of species traded live outnumbers the regulated trade by at least three times, according to some estimates.
    • To date, there have been few effective disincentives to stop traffickers from selling illegal wildlife online.

What can be done?

    • Australia and all other nations that have signed up to CITES have a responsibility to keep track of internet-based wildlife trade.
    • Since 2019 we have been monitoring the wildlife trade in Australia, drawing data from over 80 websites and forums.
    • Adam Toomes receives funding from the Australian Research Council and previously the Centre for Invasive Species Solutions.

Numinus Wellness Inc. Reports Q2 2023 Results

Retrieved on: 
Thursday, April 13, 2023

VANCOUVER, BC, April 13, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and six months ended February 28, 2023 ("Q2 2023" and "first six months").

Key Points: 
  • VANCOUVER, BC, April 13, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and six months ended February 28, 2023 ("Q2 2023" and "first six months").
  • Gross profit was $2.1 million in Q2 2023, a significant increase compared to gross profit of $0.2 million in Q2 2022.
  • At the end of Q2 2023, Numinus had 133 practitioners (Q1 2023: 138) providing client treatments through its wellness clinics and virtual services, a 3.6% decrease from the end of the previous quarter.
  • On April 11, 2023, Numinus announced the launch of its new Numinus Network wellness clinic licensing platform – providing independent practitioners with the opportunity to own and operate a Numinus branded full-service clinic.

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

Retrieved on: 
Wednesday, February 1, 2023

Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy and will use Numinus Bioscience's Psilocybin Tea, EnfiniTea, for dosing.

Key Points: 
  • Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy and will use Numinus Bioscience's Psilocybin Tea, EnfiniTea, for dosing.
  • "We're thrilled that Health Canada has provided us with their prompt approval and support in starting this important clinical trial," said Payton Nyquvest, CEO and Founder, Numinus.
  • "We're honored to offer this unique experiential clinical trial opportunity alongside our well-regarded psychedelic-assisted therapy training programs," said Paul Thielking, Chief Science Officer, Numinus.
  • Practitioners interested in learning more about Numinus' training programs are encouraged to visit www.numinus.com/services/practitioner-training or email [email protected] for more information.

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

Retrieved on: 
Thursday, December 8, 2022

Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety.

Key Points: 
  • Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety.
  • Additionally, the clinical trial will use Numinus Bioscience's EnfiniTea, a whole mushroom Psilocybe tea product, for trial dosing.
  • "We're proud to offer one of the first training programs with the option to participate in an experiential clinical trial for practitioners looking to expand their psychedelic-assisted therapy education," said Paul Thielking, Chief Science Officer, Numinus.
  • Numinus expects the clinical trial may be expanded to include additional Numinus clinic locations in the future.

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

Retrieved on: 
Tuesday, November 29, 2022

VANCOUVER, BC, Nov. 29, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and twelve months ended August 31, 2022 ("Q4 2022" and "Fiscal 2022").

Key Points: 
  • VANCOUVER, BC, Nov. 29, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and twelve months ended August 31, 2022 ("Q4 2022" and "Fiscal 2022").
  • Revenues grew 643% year-over-year to $4.2 million in Q4 2022, due primarily to the acquisition of Novamind.
  • On June 27, 2022, Numinus introduced its new logo and brand identity to unify Numinus' presence across North America.
  • At the end of Q4 2022, Numinus had 122 practitioners providing client treatments through its wellness clinics and virtual services, a 10% increase from the beginning of the quarter.